KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity (2020 - 2025)

Historic Common Equity for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $964.0 million.

  • AbCellera Biologics' Common Equity fell 1057.94% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 1057.94%. This contributed to the annual value of $1.1 billion for FY2024, which is 835.13% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Common Equity is $964.0 million, which was down 1057.94% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Common Equity ranged from a high of $1.3 billion in Q3 2022 and a low of $953.4 million during Q3 2021
  • Its 5-year average for Common Equity is $1.1 billion, with a median of $1.1 billion in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 3112.82% in 2022, then tumbled by 1057.94% in 2025.
  • Over the past 5 years, AbCellera Biologics' Common Equity (Quarter) stood at $1.0 billion in 2021, then increased by 20.23% to $1.2 billion in 2022, then fell by 6.56% to $1.2 billion in 2023, then dropped by 8.35% to $1.1 billion in 2024, then dropped by 8.72% to $964.0 million in 2025.
  • Its Common Equity was $964.0 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.